Anticoccidial Drugs Market Report 2026

The anticoccidial drugs market size has grown strongly in recent years. It will grow from $1.35 billion in 2025 to $1.45 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to high prevalence of coccidiosis in poultry, limited availability of effective drug classes, growing demand for livestock products, traditional farming practices, increasing awareness of animal health management.

The anticoccidial drugs market size is expected to see strong growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to innovation in drug delivery systems, rise in intensive poultry farming, expansion of veterinary services in emerging regions, increased government support for animal health, growth in global meat and poultry consumption. Major trends in the forecast period include development of novel anticoccidial drug formulations, increased focus on poultry health management, rising adoption of combination therapies, expansion of veterinary pharmaceutical distribution networks, enhanced regulatory compliance for veterinary drugs.

The increasing demand for meat proteins is anticipated to boost the anticoccidial drug market in the years ahead. Meat proteins occur naturally in animal muscle tissue, consisting of key amino acids vital for numerous physiological processes. This surge in demand stems from expanding populations, higher disposable incomes, urban migration, and shifting consumer tastes toward high-protein diets. Anticoccidial drugs play a crucial role in contemporary livestock production. They safeguard animal health and output, enabling farmers to fulfill the rising need for meat proteins effectively and responsibly. For instance, in October 2025, Meat And Livestock Australia Limited - a nonprofit based in Australia - reported that Australia's red meat and livestock exports rose 3.2% year-on-year in 2024, hitting $19.5 billion in value. Thus, the escalating demand for meat proteins is fueling expansion in the anticoccidial drug market.

The expansion of poultry farming is anticipated to fuel the anticoccidial drug market's growth in the future. Poultry farming involves rearing domesticated birds like chickens, turkeys, ducks, and geese for meat, eggs, and feathers. This growth stems from rising protein demand, advancements in farming methods, and expanding international trade. Anticoccidial drugs are routinely mixed into poultry feed or water to prevent coccidiosis, safeguarding birds during their early, most susceptible growth phases. For instance, in April 2024, the USDA Economic Research Service - a U.S. government agency - reported that chicken sales reached 178 million in 2023, a 4 percent increase from the year before, with turkey sales also rising by 4 percent. Thus, the surge in poultry farming is propelling the anticoccidial drug market forward.

Major companies in the anticoccidial drugs market prioritize innovative solutions, like synthetic coccidiostats, to boost efficacy, reduce resistance buildup, and tackle new issues in poultry and livestock care. A synthetic coccidiostat is a lab-created chemical compound that prevents or treats coccidiosis by blocking the growth and reproduction of coccidia parasites in animals. For example, in March 2023, Zoetis - a leading U.S. animal health firm - introduced Avi-Deccox, a redesigned synthetic coccidiostat aimed at managing coccidiosis in broiler chickens. This product focuses on key pathogens such as Eimeria acervulina and Eimeria tenella, which cause major financial losses in poultry production. It uses decoquinate as its active ingredient, just like the original Deccox. Avi-Deccox counters rising resistance from heavy ionophore use in poultry by leveraging a unique mechanism of action, delivering a stronger immediate impact.

Major companies operating in the anticoccidial drugs market are Zoetis Inc., Elanco Animal Health Incorporated, Huvepharma AD, Phibro Animal Health Corporation, Ceva Santé Animale S.A., Boehringer Ingelheim International GmbH, Merck & Co. Inc, Bayer AG, Virbac S.A., Vetoquinol SA, Intas Pharmaceuticals Ltd, Alpharma BVBA, Kepro B.V., Kemin Industries Inc., Tianjin Ringpu Bio-Technology Co. Ltd., Hester Biosciences Limited, Biovet S.A., HIPRA, Impextraco NV, Lallemand Animal Nutrition.

North America was the largest region in the anticoccidial drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anticoccidial drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anticoccidial drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the anticoccidial drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and veterinary formulations, leading to higher production costs for drug manufacturers. The segments most impacted include antibiotic and ionophore-based drugs, particularly in regions such as North America and Asia-Pacific, which rely heavily on imports. While tariffs create cost pressures, they also incentivize local manufacturing and development of domestic supply chains, potentially fostering innovation and reducing long-term dependency on imports.

The anticoccidial drugs market research report is one of a series of new reports that provides anticoccidial drugs market statistics, including anticoccidial drugs industry global market size, regional shares, competitors with a anticoccidial drugs market share, detailed anticoccidial drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anticoccidial drugs industry. This anticoccidial drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anticoccidial drugs form a group of medications designed to prevent and treat coccidiosis, an intestinal parasitic disease triggered by protozoa from the Eimeria genus. They function by disrupting key stages in the coccidia life cycle, thereby managing the infection and averting the intense intestinal harm and associated symptoms linked to the condition. In veterinary practice, especially in poultry, these drugs play a vital role in boosting animal health and productivity by addressing this common and costly issue.

The primary categories of anticoccidial drugs consist of ionophores, antibiotics, sulphonamides, chemical derivatives, and others. Ionophores represent a class of anticoccidial drugs that hinder the growth and reproduction of coccidia parasites by interfering with ion transport across cell membranes. Different drug mechanisms encompass coccidiostatic and coccidiocidal effects for diverse uses, including in poultry, swine, fish, cattle, and companion animals, via various distribution channels such as veterinary hospitals, retail pharmacies, and others.

The anticoccidial drugs market consist of sales of semduramicin, monensin, lasalocid, salinomycin, decoquinate, amprolium, clopidol, and sulfachloropyrazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.